Early prediction of future disorders in asymptomatic individ

Future personalized medicine enables presently to predict, prevent and treat precisely, efficiently and economically future emerging medical and psychological disorders.

It is generally accepted that medicine today is usually reactive in nature, rather than proactive. Because many disorders lack recognized biomarkers and are defined primarily by their symptoms, diagnoses today are based on symptomatic presentation. Diagnosis therefore often necessitates witnessing the full scope of symptoms over an extended period of time, which can extend for up to a year. The delay between the first appearing symptoms and the first professional diagnosis can thus reach up to seven years.

Delaying diagnosis until the stable appearance of a full blown symptomatic display of the disorder allows for its deterioration, and often the development of the disorder from a mild or moderate state to a severe condition. In addition to the deterioration of the disorder, delaying treatment often leads to the precipitation of secondary side effects which, together with the primary ones, make the treatment of the late-stage disorder complex, costly, painful, inefficient and partially ineffective. 

I have discovered certain hypothalamic activity changes that are a common denominator indicative of Autism, Autism Spectrum Disorder (ASD) and specific Learning Disorders (LD's) including Attention Deficit Disorder (ADD) with or without the Hyperactivity component (ADHD). Regarding these activity changes as a biomarker of these disorders, I developed a non invasive biophysical method to detect and measure them. So far, results have been obtained in a small number of cases (dozens up to several hundred, differentially across all disorders investigated) thus reflecting a solid evidence-based diagnostic system. Since the genetic basis of these changes has already been shown to be stable over time, it is possible, for the first time, to detect these disorders in seemingly healthy individuals (asymptomatic), and predict the risk of developing these disorders in the future regardless of the age of the evaluated individual.

A radical change in medicine is needed, incorporating the ability to predict, and hopefully prevent, future emerging disorders. Incorporation or assimilation of this proposed method into existing medical insurance systems could potentially save billions of dollars in professional diagnostic efforts, and would enable early-stage diagnosis and precise treatments which are more effective and simpler to execute, leading to better prognoses.

The current results must obviously be validated and replicated under blind conditions. These results, if validated, open the possibility of significantly improved diagnoses of these increasingly common disorders, and promise a better future and a more favorable life circumstances for many around the world.

My development is novel starting from the novel identification of the cerebral biomarker involved, via the recognition of the biomarker as a common denominator in several different medical as well as psychological disorders and lastly the development of the non invasive method for prediction of future emerging disorders. 

My development uses a new application of an existing technology via a novel process developed. 

Monitoring the changing activity profile of the cerebral biomarker is technology dependent. Without such technology the monitoring process could not have been done and results achieved.

For the next 12 month I intend to focus my efforts on:

1. Achieve medical and scientific corroboration via a blind experimental design. 

2. Market my development trying to assimilate it into a national or regional medical healthcare insurer.

Over the next five years I intend to:

1. Widen the acknowledgement and acceptance and usage of my development to new additional healthcare insurers.

2. Collaborate with AI companies to gather and form a big data base which could deepen our understandings of the mechanisms involved in the former mentioned disorders.

1. I intend to directly contact the governmental agencies supplying national medical healthcare.

2.Indirect contact would utilize professional conferences and professional and semi popular papers advertising. 

Presently my development helps my patients visiting my neuropsychlogical clinic by initial screening as well as longitudinal non invasive monitoring of their neurological status, medical or psychological disorders.

Assimilation of my development in national medical healthcare systems would reach and help many thousand to millions of people.

The main outcomes would focus on national screening followed by longitudinal monitoring the population which would be discovered as high risked.

We posses highly skilled professionals holding neuropsychological, biochemical-biophysical and psychoimmunological as well as computer engineering backgrounds station us at the forefront as scientific team and an entrepreneurs.

We will need strong backing in managerial sides of the project.

The first option is to charge the individual user for each test. Since we focus our efforts at the national healthcare insurers all financial issues would be governed by the healthcare system.

Alternatively is the option to manufacture a medical device which would be then sold OTC to the public with a "safe vs at risk" answers imbedded.  For  in-depth  interpretations of the results regional teams of professionals will be formed.

Advancement of my development would demand rigorous validation in a blind experimental design (1). Following would demand direct approaching regional or national healthcare insurers (2). Since Solve, potentially holds the capacity to connect both the scientific as well as business and healthcare medical worlds it seemed only obvious to apply for Solves help. Moreover, it is very favorable condition as far as I can tell if the project is run abroad as beta site.  

The first barrier to overcome would be validation of the results in a blind experimental design by an expert in the relevant field. Following the acceptance of the results and external approval, the results and potential revenues from the development should be introduced to potential interested parties.

I postulate that MIT umbrella and connections are in position to advance the project. 

A second barrier will become evident during forming the start up as a legal entity and the recruitment of professionals like CEO, CFO etc. I wish to express my vision (female CEO, preference to professionals with handicaps etc.).